DC: Developing But Debatable—Deacetylase Inhibitors for CNS Disease?
ARF.—Esther Landhuis. This is Part 2 of a two-part series. See also Part 1. None
379 RESULTS
You searched Esther
Sort By:
ARF.—Esther Landhuis. This is Part 2 of a two-part series. See also Part 1. None
percent.”—Esther Landhuis Submitted to The New York Times on 18 March 2013 To the Editors, Nearly half of the
see Bartzokis, 2004).—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=2042 Immune
14-16 October in Chicago, immediately preceding this year’s Society for Neuroscience conference.—Esther
dysfunction.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=2560 Alzheimer's Disease Clinical
conclusion is that other genes combine with APP to affect the degeneration of LC neurons.”—Esther Landhuis
May 24.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=2794 Alzheimer's Disease
brain scans, he said. “It may be possible to noninvasively follow the progression of CAA.”—Esther
correlates with increased risk of AD and vascular dementia 30 years later.—Esther Landhuis None
though that is beginning to change.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=3159
at least one copy of the high-risk E4 allele.—Esther Landhuis None
in neurons upon NMDA receptor stimulation (Marambaud et al., 2003).—Esther Landhuis None
neurodegenerative diseases right now that I think we're just starting to recognize.”—Esther Landhuis None
determine whether something was a real effect. That is where AD needs to go.”—Esther Landhuis None
February in the journal Biochemistry (Yu et al., 2009).—Esther Landhuis None